|[August 21, 2014]
Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions
CAMBRIDGE, Mass. --(Business Wire)--
Idec (NASDAQ: BIIB) today announced the appointment of Adriana
(Andi) Karaboutis as executive vice president, Technology and Business
Solutions, effective September 24, 2014. She will report directly to the
company's chief executive officer, George Scangos, Ph.D., and will be a
member of the Biogen Idec management team.
Ms. Karaboutis will lead Biogen Idec's information technology (IT)
operations and advance the company's use of technology and data to
enhance overall engagement with patients and healthcare providers. In
this new role, she will drive technology initiatives throughout the
entire organization, leading Biogen Idec's efforts to leverage advanced
analytics to inform the drug discovery process, unlock new insights from
clincal data and improve patient care through tools such as wearable
and ingestible devices.
"Andi is a remarkable technology leader who will enable Biogen Idec to
infuse digital innovation at all levels of our business and research
organizations," said Dr. Scangos. "As the pace of digital innovation
accelerates, Andi will play a critical role in our mission to improve
human health and support those who serve patients. She views data and
information as a new currency to gain insights, tailor conversations,
improve research and achieve business goals."
Ms. Karaboutis joins Biogen Idec from Dell (News - Alert) where she was vice president
and chief information officer (CIO), with responsibility for the
company's overall IT enterprise and customer experience. Her background
also includes leadership roles in global IT and business operations at
Ford Motor Company (News - Alert) and General Motors. Ms. Karaboutis received a
bachelor's of science (B.S.) in Computer Science as a Merit Scholar from
Wayne State University and has completed the accelerated Marketing
Strategy Program at Duke University's Fuqua School of Business.
About Biogen Idec
Through cutting-edge science and medicine, Biogen Idec discovers,
develops and delivers to patients worldwide innovative therapies for the
treatment of neurodegenerative diseases, hematologic conditions and
autoimmune disorders. Founded in 1978, Biogen Idec is the world's oldest
independent biotechnology company and patients worldwide benefit from
its leading multiple sclerosis and innovative hemophilia therapies. For
product labeling, press releases and additional information about the
Company, please visit www.biogenidec.com.
[ Back To TMCnet.com's Homepage ]